Der Zock hat begonnen!! hoff ihr seit dabei!! - 500 Beiträge pro Seite

[Papiga]

Hab heut schon am vormittag auf Bradley Pharma "BPRX" aufmerksam gemacht!! geht rein!! wenn die 10$ geknackt sind gehts ab!!

super chart!!

[Crashboombang]

Ist das nicht irgendeine kleine Biotech Klitsche aus den USA - die kurz vor der Pleite steht - wie so eine ganze Menge dieser US-Werte! Laß mich raten - du bißt schon seid 8 drin - und willst jetzt deine Papiere los werden - na klar - bei knapp 1,5 Mio Aktien Umsatz würde ich auch versuchen das Ding zu puschen, damit ich die SCH**** noch los werde. Sorry Leute - wenn ihr Lust habt dann shortet das Ding höchstens - dann fliegt Papiga ordentlich auf die Schnutte!!!

Grüße

CBB

[Papiga]

@Crashboom - Auf deine blöde Bemerkung hin ohne dich vorher über ein Unternehmen zu informieren, musste ich das reinstellen!! lesen kannst du ja!! wenn du oft auf die schnautze fällst, dann tust du mir leid!!


Bradley Pharmaceuticals Reports Strong Second Quarter 2001 Results: Sales Up 45%, Profit Up 185

FAIRFIELD, N.J., July 25 /PRNewswire/ -- BRADLEY PHARMACEUTICALS, INC. (Nasdaq: BPRX) today announced Net Income for the Second Quarter 2001, ending June 30, totaled approximately $548,000, an increase of $355,000, or 185% over the same period last year. Net Income per common share totaled $0.06 (diluted), compared to $0.02 (diluted) for the same three month period in 2000.

The strong positive earnings are primarily based on significant increases in Net Sales for the Second Quarter 2001, amounting to $5.9 million, an increase of $1.8 million, or 45%, over Second Quarter 2000 Net Sales of $4.1 million.

Due to the Company`s strong performance in both First and Second Quarters, Net Income for the First Half 2001 was reported as $852,000, an increase of $5.3 million over last year`s loss of ($4.49 million) for the First Half 2000, which reflected a non-cash write-down of $3.9 million in the First Quarter 2000. Net Income per common share for First Half 2001 totaled $0.10 (diluted), versus a loss of ($.57) (diluted) for the same six month period last year.

First Half 2001 Net Sales significantly increased to reach an $11.2 million level, which is $4.3 million or 63% over Net Sales for the First Half 2000.

President and CEO Daniel Glassman, stated, "We are pleased with the strong financial performance in the First Half 2001. The rapidly growing sales of Bradley products, particularly the key promoted brands of CARMOL(R)40, potent, yet gentle tissue softener, PAMINE(R) antispasmodic/anticholinergic formulated without lactose and GLUTOFAC(R)-ZX multivitamin with selected minerals, including folic acid and zinc, are a direct result of management`s focused sales and marketing strategy. The Corporation has targeted its promotional resources on prescription brands with the highest potential return on investment, and has carefully targeted physician audiences with the highest prescribing potential. This has resulted in a strong, consistent trend of reaching increasingly higher sales and numbers of new prescriptions, generally accepted by the industry as the indicator of future sales. These new highs in sales and prescriptions support management`s goal to achieve record annual sales with over 400,000 target product new prescriptions in 2001.

In the Second Half of 2001, Bradley Pharmaceuticals expects to continue to extend its presence in the marketplace. The introduction of a new larger, more economical size of LIDAMANTLE(R), in addition to a new LIDAMANTLE(R)HC with hydrocortisone product, furthers the Company`s commitment to the dermatology market. Moreover, Bradley plans three additional new dermatologic therapy product introductions in the next 18 months; entering the prescription acne therapeutic market, the largest dollar volume category within dermatology. In addition, in June 2001, the FDA approved the marketing of a new and improved lactose-free PAMINE(R) antispasmodic/anticholinergic formulation. The Company also has successfully completed a number of Phase IV medical research studies which demonstrate the safety and effectiveness advantages of Bradley therapies over their competitors.

The Management Team is confident that the current strong financial performance will continue and grow throughout 2001 and beyond."

Bradley Pharmaceuticals markets prescription and ethically-promoted non-prescription drugs throughout the US and in 33 international markets. Bradley delivers gastroenterology, nutritional and respiratory brands through its Kenwood Therapeutics division, and dermatology brands through its Doak Dermatologics subsidiary. The Company remains focused on core strengths of marketing, sales and financial control, and has achieved success by targeting unfilled marketing opportunities and introducing product line extensions to fill unmet needs. Important announcement:

Bradley Pharmaceuticals Chairman and Chief Executive Officer, Daniel Glassman, will host a conference call to discuss the 2nd Quarter earnings results on Thursday, July 26, 2001 at 8:15 AM EDT. A Question and Answer session will follow. To participate in the conference call, please dial 1-888-489-9485 approximately 10 minutes prior to the start of the call.

Playback of the conference call will be available after 10:15 AM EDT for 24 hours by calling 1-800-633-8284 and entering reservation #19188371. The call also will be available for 30 days at http://www.redchip.com.

Bradley Pharmaceuticals common stock is quoted on the NASDAQ market under the symbol BPRX.

Please visit Bradley Pharmaceuticals web site at: http://www.bradpharm.com.

This release may contain forward-looking statements that reflect management`s current views of future events and operations. These forward-looking statements are based on assumptions and external factors, including assumptions relating to regulatory action, capital requirements and competing products. Any changes in such assumptions or external factors could produce significantly different results.


LG Papiga

[Papiga]

übrigens gabs gestern dies hier:


Bradley Pharmaceuticals Upgrades Year Revenue View To $23.2 Million

FAIRFIELD, N.J. -(Dow Jones)- Bradley Pharmaceuticals Inc. (BPRX) increased its guidance for the year for the second time based on continued sales and new prescription growth.
In a press release Thursday, Bradley said it now expects 2001 net income of $ 2.11 million, or 22 cents a share, on sales of $23.2 million.

In April, the company increased its outlook for the year to net income of $ 1.78 million, or 19 cents a share, on sales of $22.4 million, up from its original projections for net income of $1.3 million, or 16 cents a share, on sales of $21.2 million.

Shares of Bradley recently traded at $9, up $1.14, or 14.5%, on Nasdaq volume of 576,200 shares. Average daily volume is 305,881 shares.

(This story was originally published by Dow Jones Newswires)


LG
Papiga

[Micky_Maus]

warum hast du das Ding nicht vor 1-2 Monaten hier reingestellt, dann wärst du jetzt der KING ! Merke: Aktien kauft man, bevor sie steigen und nicht danach ! Trotz der guten Meldungen schreit der Chart nach einer Korrektur, und vom KGV her ist eine weitere Verdopplung nicht gerechtfertigt.

[Papiga]

Das KGV für das laufende Jahr beträgt 40!! Also würde ich meinen auf die folgenden Jahre hochgerechnet liegen wir bei etwa 15-20!! Derzeit macht das Unternehmen 185% Profit!! Umsatz sollte auch weiter steigen!!

Die Korrektur gab es schon! Von 10,5$ auf 7,3$ und damals machte ich aufmerksam auf den Wert!! damals ein KGV 01 von 30!!

Sollte die 10$ in angriff genommen werden und sie wird durchbrochen, würde ich zuschlagen!!

LG
Papiga

Wenn der Wert jemanden zu hoch erscheint, dann lieber die Finger davon lassen!!

[Papiga]

Wollte nur sagen das ich BPRX, die ich empfohlen habe, heute mit 120% gewinn verkauft habe!! also bis bald!! derzeit bin ich in SABA (kann man alles nachlesen) bin bei 2,3$ rein!! kursziel ende dezember 9$!!

LG
Papiga